Skip to main content
logo
/
Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.420
+0.160 (4.91%)
Jul 22, 2025, 3:13 PM - Market open

Company Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease.

The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.
Larimar Therapeutics logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees65
CEOCarole Ben-Maimon

Contact Details

Address:
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania 19004
United States
Phone844-511-9056
Websitelarimartx.com

Stock Details

Ticker SymbolLRMR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001374690
CUSIP Number517125100
ISIN NumberUS5171251003
Employer ID20-3857670
SIC Code2834

Key Executives

NamePosition
Dr. Carole S. Ben-Maimon M.D.Chief Executive Officer, President and Director
Michael Celano CPASecretary and Chief Financial Officer
Dr. Gopi Shankar M.B.A., Ph.D.Chief Development Officer
John BermanVice President of Finance and Administration
Jennifer Spokes JohanssonVice President of Legal and Compliance
Dr. Russell G. Clayton Sr., D.O, D.O.Chief Medical Officer
Francis Michael Conway CPAVice President and Controller

Latest SEC Filings

DateTypeTitle
Jun 23, 20258-KCurrent Report
Jun 23, 20258-KCurrent Report
Jun 17, 2025SCHEDULE 13GFiling
May 14, 2025SCHEDULE 13G/AFiling
May 13, 20258-KCurrent Report
May 13, 2025SCHEDULE 13G/AFiling
May 5, 20258-KCurrent Report
Apr 30, 202510-QQuarterly Report
Apr 30, 20258-KCurrent Report
Apr 22, 2025SCHEDULE 13G/AFiling
View All SEC Filings